Nimodipine is the one medication given to virtually every patient with aneurysmal subarachnoid hemorrhage (aSAH). It is taken by mouth or through a feeding tube, 60 mg every four hours, for 21 days. The 2023 American Heart Association/American Stroke Association guidelines call early initiation of nimodipine beneficial for preventing a dangerous complication called delayed cerebral ischemia and for improving long-term functional outcomes. No other single drug carries that same universal recommendation in aSAH care.
What Nimodipine Does in the Brain
Nimodipine is a calcium channel blocker, but its role in aSAH is not simply to lower blood pressure. It works by blocking calcium from flooding into the smooth muscle cells that line blood vessels in the brain. When blood from a ruptured aneurysm sits around those vessels, it triggers intense spasms that can choke off blood flow days after the initial bleed. Nimodipine relaxes those constricted vessels and also reduces the release of substances from the vessel lining and from platelets that would otherwise make the spasms worse.
The net effect is protection against delayed cerebral ischemia, a condition where parts of the brain lose adequate blood supply roughly 4 to 14 days after the hemorrhage. This complication is one of the leading causes of disability and death in people who survive the initial bleed. A meta-analysis of 16 trials involving over 3,300 patients confirmed that nimodipine reduces this risk and improves outcomes.
The 21-Day Treatment Course
The standard regimen is 60 mg taken six times a day (every four hours) for 21 consecutive days. This schedule comes directly from landmark clinical trials dating back to 1983 and has remained essentially unchanged. The medication is given enterally, meaning by mouth or through a tube that delivers it to the stomach, because the oral form is what was studied and shown to work. Intravenous nimodipine exists in some countries but is not the standard in most of North America.
Treatment typically starts as soon as possible after the diagnosis is confirmed, often within the first day or two. Even if the aneurysm has not yet been surgically repaired, nimodipine is initiated early because the window for delayed cerebral ischemia opens within the first week.
Side Effects and Blood Pressure Concerns
Because nimodipine relaxes blood vessels, the most clinically significant side effect is low blood pressure. This is a particular concern in aSAH patients, who need adequate blood flow to the brain at all times. Blood pressure is monitored closely throughout the 21-day course, and the dose may be reduced if pressure drops too far.
The risk of hypotension increases when nimodipine is taken alongside other blood pressure medications like beta-blockers, ACE inhibitors, or diuretics. Certain drugs that slow the liver’s ability to break down nimodipine (CYP3A4 inhibitors) can also raise its concentration in the blood and amplify the blood pressure drop. Other common but generally milder side effects include headache, flushing, nausea, diarrhea, dizziness, and swelling in the feet.
Other Medications Used in aSAH Care
While nimodipine is the universal drug, patients with aSAH typically receive several other medications as part of their intensive care. These are not given to every patient in the same way nimodipine is, but they come up often enough that they are worth understanding.
Blood Pressure Control
Before the ruptured aneurysm is repaired, keeping blood pressure from spiking too high helps reduce the risk of rebleeding. Previous guidelines suggested targets below 160 or 180 mmHg systolic, though the 2023 AHA/ASA guidelines note there is not enough evidence to recommend one specific number. The key principle is to avoid sudden, dramatic drops in pressure. Intravenous medications like nicardipine (common in North America) or labetalol are frequently used for this short-term management.
Seizure Prevention
Seizures can occur in the immediate aftermath of a brain hemorrhage, so many patients receive a short course of anti-seizure medication during the first three to seven days. Levetiracetam and phenytoin are the two most commonly used drugs for this purpose. Both the AHA and the Neurocritical Care Society discourage routine long-term anti-seizure medication in aSAH patients. The prophylaxis is meant to cover the highest-risk window and then stop.
Pain Management
aSAH causes severe headache, and managing that pain matters both for comfort and because uncontrolled pain can spike blood pressure. In the ICU, the most frequently used medications are acetaminophen (paracetamol), opioids such as oxycodone or fentanyl given intravenously, and anti-inflammatory drugs. The choice of painkiller is made carefully because heavy sedation can mask neurological changes that doctors need to detect early.
Sodium Correction
A significant number of aSAH patients develop low sodium levels due to a condition called cerebral salt wasting, where the brain signals the kidneys to dump too much sodium into the urine. This leads to dehydration and electrolyte imbalance, both of which can worsen brain injury. Concentrated saline solutions are commonly used to bring sodium levels back up. Fludrocortisone, a steroid that helps the body retain sodium and water, has shown effectiveness in reducing the amount of concentrated saline needed and stabilizing fluid balance in these patients.
Why Nimodipine Stands Alone
Many drugs are used during aSAH treatment, but nimodipine is the only one with a strong, guideline-level recommendation for every patient regardless of severity or clinical situation. The others are applied based on individual need: not every patient develops dangerously high blood pressure, seizures, or sodium imbalances. Nimodipine, by contrast, is started on all aSAH patients because the risk of delayed cerebral ischemia is present in everyone who has had this type of hemorrhage, and the evidence for prevention is robust enough to make it standard care worldwide.